Table 4.
Individual PFAS prevalence study results, NHANES and Quest Diagnostics
| PFAS species | NHANES, 2017–2020, n = 3072 | Quest Diagnostics, 2023–2024, n = 1023 | ||||||
|---|---|---|---|---|---|---|---|---|
| Concentration, ng/mL | Positive, % | Concentration, ng/mL | Positive, % | |||||
| Median | Average | Highest observed | Median | Average | Highest observed | |||
| Linear PFOS | 2.70 | 4.48 | 95.10 | 99.6% | 1.17 | 1.92 | 43.9 | 98.1% |
| Branched PFOS | 1.10 | 1.63 | 19.30 | 98.7% | 0.70 | 0.95 | 8.20 | 92.5% |
| Linear PFOA | 1.30 | 1.61 | 52.80 | 99.5% | 0.90 | 1.14 | 1.94 | 97.5% |
| Branched PFOA | 0.07 | 0.08 | 0.70 | 6.3% | 0.07 | 0.07 | N/A | 0% |
| PFHxS | 1.00 | 1.57 | 48.80 | 98.6% | 0.73 | 1.07 | 27.30 | 95.0% |
| PFNA | 0.40 | 0.65 | 7.00 | 94.8% | 0.30 | 0.41 | 3.60 | 91.7% |
| PFDA | 0.20 | 0.28 | 7.30 | 80.7% | 0.07 | 0.16 | 2.90 | 45.4% |
| PFUnDA | 0.10 | 0.18 | 4.80 | 58.5% | 0.07 | 0.13 | 2.00 | 32.3% |
| MeFOSAA | 0.07 | 0.18 | 4.50 | 49.7% | 0.07 | 0.11 | 2.90 | 11.7% |